EU Joint Clinical Assessment for Orphan Drugs

Methodological Challenges, Solutions, and Early Learnings

Are you prepared to navigate the complexities of Joint Clinical Assessment (JCA) in the EU for your rare disease product? Join our webinar to hear from our panel of experts with extensive experience supporting clients with their EU JCA strategy, training, PICO prediction, and submission development. With years of deep expertise in orphan drugs, our panel will guide you through the essential steps to develop a successful JCA strategy in rare disease.

Learning Objectives:

Get an overview of the JCA guidelines and why they will be particularly challenging for orphan drugs.
Understand the methodological complexities of working with rare disease data.
See how our 5-step strategic solution can help you prepare for your submission.
Hear what we have learned from JCA projects currently underway.

Event hosted September 24, 2025